A

Ascentage Pharma Group International
6855

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
HK$21.37B
EV
HK$21.81B
Shares Outstanding
345.36M
Beta
0.78

Wall Street View

Analyst Rating
BUY
Analyst Target Price
HK$53.87
P/E 2025E
-
P/Revenue 2025E
37.25x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Ascentage Pharma Group International

gainify

A

Ascentage Pharma Group International

6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting...

Sector

Healthcare

Industry

Biotechnology

CEO

Yang, Dajun

Employees

567

IPO Date

2019-10-28

Headquarters

Suzhou Industrial Park, 68 Xinqing Road, Suzhou, Jiangsu Province, 215000, China

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.